Author Interviews, Heart Disease, JACC, Surgical Research / 28.10.2016
Study Supports Feasibility of TAVI for High-Risk Aortic Regurgitation
MedicalResearch.com Interview with:
Anna Franzone, MD and
Prof.Thomas Pilgrim, MD
Department of Cardiology
Bern University Hospital
INSELSPITAL
Bern, Switzerland
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Surgical aortic valve replacement is the therapeutic standard for patients with pure native aortic regurgitation (AR). However, transcatheter aortic valve implantation (TAVI) is emerging as a novel treatment option for patients deemed inoperable or at high-risk for surgery because of advanced age and multiple comorbidities. We performed a systematic review and meta-analysis including 237 patients with pure native AR undergoing TAVI across 13 studies. The primary study endpoint, all-cause mortality at 30-day, ranged from 0% up to 30% with a summary estimate rate of 7% . The occurrence of complications such as the need for a second valve implantation was relatively low as well as the rates of other endpoints (cerebrovascular events, major bleeding and vascular complications).
(more…)